Fig. 4: Cardiovascular toxicity comparisons for immunotherapies targeting Acute Lymphocytic Leukemia (ALL).
From: Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers
Reporting odds ratios were compared for significant adverse reactions between tisagenlecleucel (N = 219 reports) and blinatumomab (N = 28 reports) for pediatric ALL patients (aged 17 or younger). Significant adverse reactions include tachycardia (n = 17 reports [tisagenlecleucel] and n = 2 reports [blinatumomab]), sinus tachycardia (n = 5 reports [tisagenlecleucel] and n = 2 reports [blinatumomab]), pericardial effusion (n = 3 reports [tisagenlecleucel] and n = 3 reports [blinatumomab]), and hypotension (n = 72 reports [tisagenlecleucel] and n = 5 reports [blinatumomab]). Error bars denote 95% confidence intervals.
